This article is more than 5 years old. Information may no longer be current.

PIQUR collaborates with Pierre Fabre on dermato-oncologic inhibitor

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Pierre Fabre has signed a collaborative agreement with PIQUR to develop the company’s lead dermato-oncology compound PQR309, according to a press release.

PQR309 is an oral, brain-penetrant, dual inhibitor of the PI3K/mTOR pathway that crosses the blood-brain barrier. PQR309 has been shown to have favorable safety, tolerability and pharmacokinetic profile in both preclinical and phase 1 trials.

For the first stage of the collaboration, Pierre Fabre’s research and development teams will work with PIQUR to evaluate and develop the dermatological formulations of PI3K/mTOR inhibitors for multiple therapeutic indications.

Following this, Pierre Fabre will have the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions, according to the release.

“The collaboration with Pierre Fabre, a worldwide leader in dermatology, is an important milestone for PIQUR, validating its potential to bring novel solutions to patients for the treatment of dermato-oncology diseases with unmet medical needs,” Hervé Girsault, chief business officer of PIQUR, said in the release.

Reference: www.piqur.com; www.pierre-fabre.com